Strona główna
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Progress in Neurotherapeutics and Neuropsychopharmacology: Volume 1, 2006

Progress in Neurotherapeutics and Neuropsychopharmacology: Volume 1, 2006

9780521862530
743,40 zł
669,06 zł Zniżka 74,34 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 669,06 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.
Szczegóły produktu
Cambridge University Press
99149
9780521862530
9780521862530

Opis

Rok wydania
2006
Numer wydania
1
Oprawa
twarda
Liczba stron
184
Wymiary (mm)
179.00 x 254.00
Waga (g)
500
  • Preface J. L. Cummings; Introduction to neurotherapeutics and neuropharmacology J. L. Cummings; 1. Rivastigmine in the treatment of dementia associated with Parkinsons disease:: a randomized, double-blind, placebo-controlled study S. Tekin and R. Lane; 2. Modafinil for the treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M. Clanet; 3. Radiotherapy with concurrent and adjuvant temozolomide:: a new standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff and R Stupp; 4. Treating migraine attacks ASAP:: concept and methodological issues N. J. Wiendels and M. D. Ferrari; 5. Early phase trials of minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H. Moore and R. G. Miller; 6. Creatine as a potential treatment for amyotrophic lateral sclerosis J. M. Shefner; 7. AVP-923 as a novel treatment for pseudobulbar affect ALS L. E. Pope; 8. Liquid fluoxetine vs. placebo for repetitive behaviors in childhood autism E. Hollander, E. Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman; 9. Testing multiple novel mechanisms for treating schizophrenia in a single trial H. Y. Meltzer; 10. Selegiline in the treatment of negative symptoms of schizophrenia A. Lin and A. Bodkin; 11. Analysis of the cognitive enhancing effects of modafinil in schizophrenia D. C. Turner and B. J. Sahakian; 12. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatient with schizophrenia or schizoaffective disorder:: results of a double-blind, 6-week study, with a 6-month, double-blind, continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.
Komentarze (0)

  • Często kupowane razem

    Brak dostępnych produktów